Competitive Salary: The Medicines and Healthcare products Regulatory Agency (MHRA): We are currently looking for a confident Section Leader to lead a Bioinformatics Team in.... South Mimms, Potters Bar

Notice NOT-TR-21-012 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-DE-21-002 from the NIH Guide for Grants and Contracts. The purpose of this initiative is to support intervention research aimed at equipping the dental workforce in meeting the unique needs of people living with HIV (PLWH) or at risk of contracting HIV. This initiative aligns with the United States Department of Health and Human Services (DHHS) plan, Ending the HIV Epidemic: A Plan for America, which identifies four broad goals: 1) Diagnose individuals infected with HIV as soon as possible after infection; 2) Treat HIV infection rapidly and effectively to achieve sustained viral suppression; 3) Protect people at risk for HIV using potent and proven prevention strategies, including Pre-exposure Prophylaxis (PrEP); and 4) Respond rapidly to detect growing HIV clusters and to prevent new HIV infections. Dental care providers may have unique opportunities to contribute to these efforts, but there are also significant challenges. Among the most commonly-cited challenges are concerns about patient acceptability, the need for appropriate provider training and support, fitting HIV-related services into the dental clinic workflow, complex and variable laws related to HIV service-provision, and billing and reimbursement systems necessary for sustainability. Applications in response to this FOA should propose to develop, adapt, and/or test interventions to equip dental care providers to participate in and/or to provide HIV-related services, consistent with those identified in the DHHS plan. Proposed interventions should address one or more challenges currently preventing greater participation by dental care providers, and can aim to overcome barriers at any relevant socioecological level (e.g., individual patient or provider, community, clinic, care organization). Awards made under this FOA will initially support a milestone-driven planning phase (UG3) for up to 2 years, with possible transition to a clinical trial implementation phase of up to five years (UH3).

Competitive Salary: F. Hoffmann-La Roche AG: At Roche we believe it’s urgent to deliver medical solutions right now – even as we develop innovations for the future. We are passionate about trans Switzerland (CH)

Funding Opportunity PAR-21-093 from the NIH Guide for Grants and Contracts. The purpose of the NIDCD Research Dissertation Fellowship for Au.D. Audiologists (F32) program is to support a comprehensive, rigorous biomedical research training, and dissertation research leading to a research doctorate (i.e., Ph.D.) in the biomedical, behavioral, or clinical sciences. This Funding Opportunity Announcement (FOA) does not allow applicants to propose to lead an independent clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor.

Assist software team in designing interfaces and visualizations for mutational data analysis. Understanding of algorithms used in the analysis of NGS data.
From Resolution Bioscience - Mon, 14 Dec 2020 15:26:56 GMT - View all Kirkland, WA jobs

Funding Opportunity RFA-AG-22-001 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications specific to infrastructure to support the Alzheimer's Disease Sequencing Project (ADSP) and related to data collection, longitudinal follow-up, ascertainment of antecedent risk factors, and the characterization of additional relatives from families multiply affected by Alzheimer's disease and related dementias (AD/ADRD) in order to expand the existing NIA Late Onset of AD Family Based Study sample set.

Competitive Salary: EMBL: Data Coordination and Archiving Presentation Technology Project Lead Cambridge, Cambridgeshire, England

Competitive Salary: EMBL: Bioinformatics Developer Location: Cambridge, Cambridgeshire, England

(4) Laboratory expertise with nucleic acid microarrays, next gen sequencing, STR analysis, aptamers, bioinformatics, and data analysis is a plus; $20 - $30 an hour
From Indeed - Fri, 11 Dec 2020 22:15:28 GMT - View all Madison, WI jobs

Competitive Salary: F. Hoffmann-La Roche AG: At Roche we believe it’s urgent to deliver medical solutions right now – even as we develop innovations for the future. We are passionate about Switzerland (CH)

Notice NOT-OD-21-041 from the NIH Guide for Grants and Contracts

Notice NOT-OH-21-008 from the NIH Guide for Grants and Contracts

Notice NOT-CA-21-023 from the NIH Guide for Grants and Contracts

Notice NOT-CA-21-019 from the NIH Guide for Grants and Contracts

range £36,028 – £40,125 per annum including London Allowance, superannuable: University College London (UCL): Applications are invited for a Research Fellow Biostatistician in the Department of Clinical and Experimental Epilepsy... London (Central), London (Greater)

Degree in biomedical, social, behavioral sciences, public health, bioinformatics, computer science or related field, preferred.
From University of Wisconsin–Madison - Fri, 11 Dec 2020 06:57:33 GMT - View all Madison, WI jobs

Notice NOT-CA-21-022 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-21-097 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) for R34 planning grant applications focuses on prevention and intervention strategies for fetal alcohol spectrum disorders (FASD) throughout the lifespan. The intent of this FOA is to support research that advances (1) prevention approaches to reduce prenatal alcohol exposure and incidence of FASD and (2) interventions for FASD. It is expected that research conducted via this mechanism will consist of studies that are a pre-requisite for preparing and submitting subsequent applications for larger scale FASD prevention or intervention studies. Applicants interested in exploratory phased projects may consider FOA (PAR-21-NNN, the R61/R33 option).

Funding Opportunity PAR-21-098 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) focuses on prevention and intervention strategies for fetal alcohol spectrum disorders (FASD) throughout the lifespan. The intent of this FOA is to support research that advances (1) prevention approaches to reduce prenatal alcohol exposure and the incidence of FASD and that (2) interventions for FASD. These objectives will be accomplished with the Exploratory/Developmental Phased Award (R61/R33) mechanism, clinical trial optional. The R61 phase will support pilot studies or secondary data analysis for hypothesis development and feasibility, and research testing the hypotheses can be expanded in the R33 phase. The transition to the R33 phase will be determined by NIAAA program staff after evaluation of the achievement of specific milestones set for the R61 phase. Highest priority will be given to applications with clinical trials. Applicants interested in planning clinical trials or adding to current projects may also consider FOA (PAR-21-NNN, the R34 option).